SPIt does appear that the expiry of Pfizer's 90 day exclusivity period is having a detrimental affect on the stock.
Many investors are interpreting this as an indication that Pfizer is no longer interested in ONC, and that the data will be less than impressive.
They may be correct. Too bad.